Gouty arthritis
Drug research and approvals for gouty arthritis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 12 studies of gouty arthritis are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and the EU has 3 authorised medicines for it.
- Recruiting worldwide: 12
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 3
- ACUTE-GO is a Study Testing the Effectiveness and Safety of Two Doses of Purified Cortrophin Gel in Patients With Acute…NCT07938164 · Phase 4 · ANI Pharmaceuticals · starts Jan 28, 2026
- A Study of Efficacy and Safety of IBI3011 in Subjects With Acute Gouty ArthritisNCT07842497 · Phase 2 · Innovent Biologics (Suzhou) Co. Ltd. · starts Oct 29, 2026
- Clinical Study of HRS-2129 for Acute Gouty ArthritisNCT07706777 · Phase 2 · Shandong Suncadia Medicine Co., Ltd. · starts Aug 19, 2026
- A Study to Evaluate the Efficacy,Safety,Tolerability,Pharmacokinetics,and Immunogenicty of Plonmarlimab in Subjects…NCT07453004 · Phase 2 · TJ Biopharma Co., Ltd. · starts Mar 26, 2026
- Purified Cortrophin® Gel Efficacy and Safety Study of 2 Dose Levels in Patients With Acute Gout FlaresNCT07346079 · Phase 4 · Massachusetts General Hospital · starts Dec 20, 2025
- Digital Care for Holistic Health in Older Adults With Diabetes and MultimorbidityNCT07310849 · Not applicable · Chang Gung University of Science and Technology · starts May 12, 2026
- Clinical Assessment for Rheumatologic Disease - Research and Advancement in Safety and EfficacyNCT07150000 · Not reported · University of Bonn · starts Apr 1, 2025
- Nurse-Led Telehealth for GoutNCT06971146 · Not applicable · University of Aarhus · starts Oct 1, 2025
- Metformin in Safety and Efficacy in Gouty PatientsNCT06924658 · Phase 2 · Mostafa Bahaa · starts Apr 20, 2025
Approved 8
- IndomethacinCyclooxygenase inhibitor
- NaproxenCyclooxygenase inhibitor
- FebuxostatXanthine dehydrogenase inhibitor
- PrednisoneGlucocorticoid receptor agonist
- Triamcinolone acetonideGlucocorticoid receptor agonist
- Dexamethasone phosphoric acidGlucocorticoid receptor agonist
- DexamethasoneGlucocorticoid receptor agonist
- CanakinumabInterleukin-1 beta inhibitor
How its trials ended
50 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 7 whose ending is known, 0% met their primary endpoint, 14% missed it and 86% stopped early.
- Completed, result not reported2142%
- Ongoing1326%
- Status unknown918%
- Stopped: other or unclear48%
- Missed its primary endpoint12%
- Stopped: lack of efficacy12%
- Stopped: enrollment or feasibility12%
| Mar 28, 2019 | Febuxostat KrkaFebuxostat · generic | KRKA tovarna zdravil d.d. Novo mesto | EMA ↗ |
| Jun 15, 2017 | Febuxostat Viatris (previously Febuxostat Mylan)Febuxostat · generic | Viatris Limited | EMA ↗ |
| Apr 21, 2008 | AdenuricFebuxostat | Menarini International Operations Luxembourg S.A. (MIOL) | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA